From ground-breaking research to revolutionary prognostics and diagnostics AMLo Biosciences is translating ground-breaking research in cancer biomarkers into a revolutionary range of prognostic and companion diagnostic products to improve patient outcomes and reduce the financial burden of cance ...
Location: United Kingdom, England, Newcastle upon Tyne
Total raised: $3.2M
Investors 2
| Date | Name | Website |
| - | Esperante | esperante.... |
| - | Northstar ... | northstarv... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.04.2022 | - | $3.2M | Future Pla... |
Mentions in press and media 5
| Date | Title | Description |
| 12.09.2022 | 15 U.K.-Based Venture Capital Investors Supporting Underrepresented Founders | These 15 U.K.-based angels and venture capital investors are worth following on the topic of ... [+] investment in underrepresented foundersVARIOUS |
| 22.04.2022 | Exclusive: AngelList raises $44 million from 10% of its customers | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. When raising capital from your customers, it doesn’t hurt when they happen to be thousands of gen... |
| 21.04.2022 | Newcastle’s AMLo gets £2.45 million-shot to facilitate early-stage skin cancer test | UK-based medical device company that specialises in the early detection of skin cancers, AMLo Biosciences (AMLo) has brought in an investment of £2.45 million. The round saw the participation of Ascension’s Life Fund and Conduit’s EIS Impac... |
| - | Newcastle’s AMLo gets £2.45 million-shot to facilitate early-stage skin cancer test | UK-based medical device company that specialises in the early detection of skin cancers, AMLo Biosciences (AMLo) has brought in an investment of £2.45 million. The round saw the participation of Ascension’s Life Fund and Conduit’s EIS Impac... |
| - | Amlo Biosciences | “From ground-breaking research to revolutionary prognostics and diagnostics AMLo Biosciences is translating ground-breaking research in cancer biomarkers int ...” |